Mireille Van Gele
Overview
Explore the profile of Mireille Van Gele including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
843
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ablinger M, Lettner T, Friedl N, Potocki H, Palmetzhofer T, Koller U, et al.
Int J Mol Sci
. 2021 Apr;
22(7).
PMID: 33805154
Intermediate junctional epidermolysis bullosa caused by mutations in the gene is characterized by the frequent development of blisters and erosions on the skin and mucous membranes. The rarity of the...
2.
Sundahl N, De Wolf K, Kruse V, Meireson A, Reynders D, Goetghebeur E, et al.
Int J Radiat Oncol Biol Phys
. 2018 Feb;
100(4):906-915.
PMID: 29485070
Purpose: To report the results of a phase 1 trial evaluating the safety of the ipilimumab/radiation therapy combination in patients with metastatic melanoma. Patients And Methods: Thirteen patients with metastatic...
3.
Desmet E, Van Gele M, Grine L, Remaut K, Lambert J
Exp Dermatol
. 2017 Aug;
27(5):463-469.
PMID: 28833576
RNA interference has emerged as a powerful tool for therapeutic gene silencing, as it offers the possibility to silence virtually any known pathology-causing gene. However, in vivo delivery of RNAi...
4.
Sundahl N, De Wolf K, Rottey S, Decaestecker K, De Maeseneer D, Meireson A, et al.
J Transl Med
. 2017 Jul;
15(1):150.
PMID: 28662677
Background: Current first-line standard of therapy for metastatic urothelial carcinoma is platinum-based combination chemotherapy. Pembrolizumab in phase III has demonstrated a promising overall response rate of 21.1% in patients with...
5.
Desmet E, Ramadhas A, Lambert J, Van Gele M
Exp Biol Med (Maywood)
. 2017 Jun;
242(11):1158-1169.
PMID: 28585891
Psoriasis is a complex chronic immune-mediated inflammatory cutaneous disease associated with the development of inflammatory plaques on the skin. Studies proved that the disease results from a deregulated interplay between...
6.
De Wolf K, Kruse V, Sundahl N, Van Gele M, Chevolet I, Speeckaert R, et al.
J Transl Med
. 2017 Feb;
15(1):21.
PMID: 28137295
Background: Antibodies blocking programmed cell death 1 (PD-1) have encouraging responses in patients with metastatic melanoma. Response to anti-PD-1 treatment requires pre-existing CD8+ T cells that are negatively regulated by...
7.
Alves De Medeiros A, Speeckaert R, Desmet E, Van Gele M, De Schepper S, Lambert J
PLoS One
. 2016 Oct;
11(10):e0164080.
PMID: 27711196
The recent interest and elucidation of the JAK/STAT signaling pathway created new targets for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical formulations have shown...
8.
Desmet E, Bracke S, Forier K, Taevernier L, Stuart M, De Spiegeleer B, et al.
Data Brief
. 2016 Jul;
7:1204-10.
PMID: 27408923
This article contains original data, figures and methods used in the characterization of the liposomal carrier 'DDC642' for topical applications, described in "An elastic liposomal formulation for RNAi-based topical treatment...
9.
Desmet E, Van Gele M, Lambert J
Expert Opin Drug Deliv
. 2016 Jun;
14(1):109-122.
PMID: 27348356
In the treatment of dermatological disorders, topical drug administration is a mainstay. However, nanoparticle-based carrier systems could improve and expand the current therapeutic range via localized delivery of active ingredients....
10.
Van Gele M, Bracke S, Alves De Medeiros A, Lambert J
Eur J Dermatol
. 2016 Apr;
26(2):195-8.
PMID: 27098680
No abstract available.